NASDAQ: KA - Kineta, Inc.

半年間の収益性: -18.63%
セクタ: Healthcare

プロモーションスケジュール Kineta, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Kineta, Inc., a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer.

さらに詳しく
It is also developing anti-CD27 agonist mAb immunotherapy, which is in Phase 1 clinical trials for the treatment of advanced solid tumors, such as renal cell carcinoma, ovarian cancer, and colorectal cancer. In addition, the company develops immunotherapies for pain management and anti-viral therapy for the treatment of emerging diseases. Kineta, Inc. has collaboration and license agreements with MSD International Business GmbH, and GigaGen, Inc. The company was formerly known as Lecura, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

EBITDA -0.0597
EV/EBITDA -1.78
IPO date 2016-02-11
ISIN US49461C1027
Industry Biotechnology
P/BV 1.89
P/S 23.63
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.005
Див.доход ао 0
Дивиденд ао 10.01
Сайт https://kinetabio.com
Цена ао 0.5521
Число акций ао 0.01105 млрд
1日あたりの価格変動: 0% (0.4801)
週ごとの価格変動: 0% (0.4801)
月ごとの料金変更: 0% (0.4801)
3ヶ月間の価格変動: -14.27% (0.56)
半年間の価格変動: -18.63% (0.59)
年間の価格変動: -86.77% (3.63)
3年間の価格推移: -85.09% (3.22)
5年間の価格推移: -74.6% (1.89)
10年間の価格推移: 0% (0.4801)
年初からの価格変動: 0% (0.4801)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 8.12 1
P/BV 14.45 1
P/E 0 0
EV/EBITDA -2.52 0
合計: 4

効率

名前 意味 学年
ROA, % -137.14 0
ROE, % -487.85 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0.5 5
合計: 2.35

義務

名前 意味 学年
Debt/EBITDA -0.0838 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % 8.84 2
収益性 Ebitda, % -73.68 0
収益性 EPS, % -99.21 0
合計: 0.4
さらに詳しく

機関 音量 共有, %
Armistice Capital, LLC 825792 7.53
Vanguard Group Inc 151380 1.38
FMR, LLC 123719 1.13
Geode Capital Management, LLC 50584 0.46
Northern Trust Corporation 36880 0.34
Stifel Financial Corporation 21853 0.2
Financial Advocates Investment Management 21744 0.2
Blackrock Inc. 19957 0.18
Renaissance Technologies, LLC 19044 0.17
ELEMENT POINTE ADVISORS, LLC 17696 0.16



スーパーバイザー 役職 支払い 生年
Mr. Craig W. Philips President & Secretary 541.67k 1961 (64 年)
Ms. Pauline Kenny Esq., J.D. Advisor 349.72k 1974 (51 年)
Mr. Keith A. Baker Chief Financial Officer 485.75k 1967 (58 年)
Dr. Thierry Guillaudeux Ph.D. Chief Scientific Officer N/A 1968 (57 年)
Mr. Gary Gentges Executive Vice President of Corporate Development

住所: United States, Seattle. WA, 219 Terry Ave. N - Googleマップで開く, Yandexマップを開く
Webサイト: https://kinetabio.com